Taiwan is on track to meet its pineapple export target of 30,000 tons this year, having exported 18,222 tons so far, with 11,286 tons or 61.9 percent sold to Japan.
The 11,286 tons sold to Japan exceed the total sold to the country in the past decade.
Taiwan is re-entering the South Korean market after a few years of hiatus and the US has also become a new market for the fruit..
Before showing a favorable response to Taiwanese pineapples, South Korea used to import pineapples from the Philippines and Indonesia, according to Department of International Affairs Director Lin Chia-jung.
Taiwan's Council of Agriculture (COA) would work with some businesses to promote the fruit in South Korea, which would be a prioritized market next year, he added.
The council would also promote a mango-pineapple hybrid to farther countries as the Taiwanese golden diamond pineapple is not suitable for long-distance transportation.
After China suspended imports of Taiwanese pineapples in March, Taiwan's Council of Agriculture (COA) has worked to expand other export channels.


Enflame Shares Surge 200% in Shanghai AI Chip Debut
China’s Global Times Slams Anthropic CEO’s AI Slowdown Plan as ‘Cold War’ Strategy
EUR/USD Eyes 1.17 as Fed Decision Could Weigh on Dollar
Volkswagen Job Cuts Put Lower Saxony Leader Under Political Pressure
UK Businesses Urge Government to Cut Electricity Levies
Meta’s AI Shopping Push Grows as Agentic Commerce Remains Below 1%
Optus Apologises After Network Outage Disrupts Emergency Calls
Asian Tech Stocks Slide as AI Concerns and Rising Bond Yields Hit Chipmakers
Samsung, Qualcomm 2nm Chip Deal Delayed Over Pricing
Gulf Ministers to Meet Iran in Oman Over Hormuz Shipping Deal
Oil Prices Surge as Houthi Attacks Raise Saudi Supply Fears
Dollar Rises as Fed Hike Bets Weigh on Asian Currencies
Boeing, SPEEA Reach Tentative Four-Year Labor Deal
China Industrial Output Beats Forecasts as Exports Support Growth
German 2-Year Yield Hits 2023 High as Rate Hike Bets Rise
US Treasury Yields Near 5% as Oil Fuels Inflation Fears
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 



